th or without fingernail involvement, due to dermatophytes (tinea unguium), and onychomycosis of the fingernail due to dermatophytes (tinea unguium). prior to initiating treatment, appropriate nail specimens for laboratory testing (koh preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis (see clinical pharmacology : special populations, contraindications , warnings , and adverse reactions : post-marketing experience for more information). description of clinical studies: blastomycosis: analyses were conducted on data from two open-label, non-concurrently controlled studies (n=73 combined) in patients with normal or abnormal immune status. the median dose was 200 mg/day. a response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 6 months. results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of blastomycosis compared with the natural history of untreated cases. histoplasmosis: analyses were conducted on data from two open-label, non-concurrently controlled studies (n=34 combined) in patients with normal or abnormal immune status (not including hiv-infected patients). the median dose was 200 mg/day. a response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 12 months. results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of histoplasmosis, compared with the natural history of untreated cases. histoplasmosis in hiv-infected patients: data from a small number of hiv-infected patients suggested that the response rate of histoplasmosis in hiv-infected patients is similar to that of non-hiv-infected patients. the clinical course of histoplasmosis in hiv-infected patients is more severe and usually requires maintenance therapy to prevent relapse. aspergillosis: analyses were conducted on data from an open-label, “single-patient-use” protocol designed to make itraconazole available in the u.s. for patients who either failed or were intolerant of amphotericin b therapy (n=190). the findings were corroborated by two smaller open-label studies (n=31 combined) in the same patient population. most adult patients were treated with a daily dose of 200 to 400 mg, with a median duration of 3 months. results of these studies demonstrated substantial evidence of effectiveness of itraconazole as a second-line therapy for the treatment of aspergillosis compared with the natural history of the disease in patients who either failed or were intolerant of amphotericin b therapy. onychomycosis of the toenail: analyses were conducted on data from three double-blind, placebo-controlled studies (n=214 total; 110 given itraconazole capsules) in which patients with onychomycosis of the toenails received 200 mg of itraconazole capsules once daily for 12 consecutive weeks. results of these studies demonstrated mycologic cure, defined as simultaneous occurrence of negative koh plus negative culture, in 54% of patients. thirty-five percent (35%) of patients were considered an overall success (mycologic cure plus clear or minimal nail involvement with significantly decreased signs) and 14% of patients demonstrated mycologic cure plus clinical cure (clearance of all signs, with or without residual nail deformity). the mean time to overall success was approximately 10 months. twenty-one percent (21%) of the overall success group had a relapse (worsening of the global score or conversion of koh or culture from negative to positive). onychomycosis of the fingernail: analyses were conducted on data from a double-blind, placebo-controlled study (n=73 total; 37 given itraconazole capsules) in which patients with onychomycosis of the fingernails received a 1-week course of 200 mg of itraconazole capsules b.i.d., followed by a 3-week period without itraconazole capsules, which was followed by a second 1-week course of 200 mg of itraconazole capsules b.i.d. results demonstrated mycologic cure in 61% of patients. fifty-six percent (56%) of patients were considered an overall success and 47% of patients demonstrated mycologic cure plus clinical cure. the mean time to overall success was approximately 5 months. none of the patients who achieved overall success relapsed.

ugs with itraconazole is contraindicated (see boxed warning , contraindications , and precautions : drug interactions ). cardiac disease: itraconazole capsules should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (chf) or a history of chf. itraconazole capsules should not be used for other indications in patients with evidence of ventricular dysfunction unless the benefit clearly outweighs the risk. for patients with risk factors for congestive heart failure, physicians should carefully review the risks and benefits of itraconazole therapy. these risk factors include cardiac disease such as ischemic and valvular disease; significant pulmonary disease such as chronic obstructive pulmonary disease; and renal failure and other edematous disorders. such patients should be informed of the signs and symptoms of chf, should be treated with caution, and should be monitored for signs and symptoms of chf during treatment. if signs or symptoms of chf appear during administration of itraconazole capsules, discontinue administration. itraconazole has been shown to have a negative inotropic effect. when itraconazole was administered intravenously to anesthetized dogs, a dose-related negative inotropic effect was documented. in a healthy volunteer study of itraconazole intravenous infusion, transient, asymptomatic decreases in left ventricular ejection fraction were observed using gated spect imaging; these resolved before the next infusion, 12 hours later. itraconazole has been associated with reports of congestive heart failure. in post-marketing experience, heart failure was more frequently reported in patients receiving a total daily dose of 400 mg although there were also cases reported among those receiving lower total daily doses. calcium channel blockers can have negative inotropic effects which may be additive to those of itraconazole. in addition, itraconazole can inhibit the metabolism of calcium channel blockers. therefore, caution should be used when co-administering itraconazole and calcium channel blockers due to an increased risk of chf. concomitant administration of itraconazole and felodipine or nisoldipine is contraindicated. cases of chf, peripheral edema, and pulmonary edema have been reported in the post-marketing period among patients being treated for onychomycosis and/or systemic fungal infections (see clinical pharmacology : special populations, contraindications , precautions : drug interactions, and adverse reactions : post-marketing experience for more information). interaction potential: itraconazole has a potential for clinically important drug interactions. co-administration of specific drugs with itraconazole may result in changes in efficacy of itraconazole and/or the co-administered drug, life-threatening effects and/or sudden death. drugs that are contraindicated, not recommended or recommended for use with caution in combination with itraconazole are listed in precautions: drug interactions. interchangeability: itraconazole capsules and itraconazole oral solution should not be used interchangeably. this is because drug exposure is greater with the oral solution than with the capsules when the same dose of drug is given. in addition, the topical effects of mucosal exposure may be different between the two formulations. only the oral solution has been demonstrated effective for oral and/or esophageal candidiasis.

3 days of treatment. treatment should be continued for a minimum of three months and until clinical parameters and laboratory tests indicate that the active fungal infection has subsided. an inadequate period of treatment may lead to recurrence of active infection. itraconazole capsules and itraconazole oral solution should not be used interchangeably. only the oral solution has been demonstrated effective for oral and/or esophageal candidiasis. treatment of onychomycosis: toenails with or without fingernail involvement: the recommended dose is 200 mg (2 capsules) once daily for 12 consecutive weeks. treatment of onychomycosis: fingernails only: the recommended dosing regimen is 2 treatment courses, each consisting of 200 mg (2 capsules) b.i.d. (400 mg/day) for 1 week. the courses are separated by a 3-week period without itraconazole capsules. use in patients with renal impairment: limited data are available on the use of oral itraconazole in patients with renal impairment. caution should be exercised when this drug is administered in this patient population (see clinical pharmacology : special populations and precautions ). use in patients with hepatic impairment: limited data are available on the use of oral itraconazole in patients with hepatic impairment. caution should be exercised when this drug is administered in this patient population (see clinical pharmacology : special populations, warnings , and precautions ).

ocompromised or receiving multiple concomitant medications. treatment was discontinued in 10.5% of patients due to adverse events. the median duration before discontinuation of therapy was 81 days (range: 2 to 776 days). the table lists adverse events reported by at least 1% of patients. table 2: clinical trials of systemic fungal infections: adverse events occurring with an incidence of greater than or equal to 1% body system/adverse event incidence (%) (n=602) gastrointestinal nausea 11 vomiting 5 diarrhea 3 abdominal pain 2 anorexia 1 body as a whole edema 4 fatigue 3 fever 3 malaise 1 skin and appendages rash* 9 pruritus 3 central/peripheral nervous system headache 4 dizziness 2 psychiatric libido decreased 1 somnolence 1 cardiovascular hypertension 3 metabolic/nutritional hypokalemia 2 urinary system albuminuria 1 liver and biliary system hepatic function abnormal 3 reproductive system, male impotence 1 * rash tends to occur more frequently in immunocompromised patients receiving immunosuppressive medications. adverse events infrequently reported in all studies included constipation, gastritis, depression, insomnia, tinnitus, menstrual disorder, adrenal insufficiency, gynecomastia, and male breast pain. adverse events reported in toenail onychomycosis clinical trials patients in these trials were on a continuous dosing regimen of 200 mg once daily for 12 consecutive weeks. the following adverse events led to temporary or permanent discontinuation of therapy. table 3: clinical trials of onychomycosis of the toenail: adverse events leading to temporary or permanent discontinuation of therapy adverse event incidence (%) itraconazole (n=112) elevated liver enzymes (greater than twice the upper limit of normal) 4 gastrointestinal disorders 4 rash 3 hypertension 2 orthostatic hypotension 1 headache 1 malaise 1 myalgia 1 vasculitis 1 vertigo 1 the following adverse events occurred with an incidence of greater than or equal to 1% (n=112): headache: 10%; rhinitis: 9%; upper respiratory tract infection: 8%; sinusitis, injury: 7%; diarrhea, dyspepsia, flatulence, abdominal pain, dizziness, rash: 4%; cystitis, urinary tract infection, liver function abnormality, myalgia, nausea: 3%; appetite increased, constipation, gastritis, gastroenteritis, pharyngitis, asthenia, fever, pain, tremor, herpes zoster, abnormal dreaming: 2%. adverse events reported in fingernail onychomycosis clinical trials patients in these trials were on a dosing regimen consisting of two 1-week treatment periods of 200 mg twice daily, separated by a 3-week period without drug. the following adverse events led to temporary or permanent discontinuation of therapy. table 4: clinical trials of onychomycosis of the fingernail: adverse events leading to temporary or permanent discontinuation of therapy adverse event incidence (%) itraconazole (n=37) rash/pruritus 3 hypertriglyceridemia 3 the following adverse events occurred with an incidence of greater than or equal to 1% (n=37): headache: 8%; pruritus, nausea, rhinitis: 5%; rash, bursitis, anxiety, depression, constipation, abdominal pain, dyspepsia, ulcerative stomatitis, gingivitis, hypertriglyceridemia, sinusitis, fatigue, malaise, pain, injury: 3%. adverse events reported from other clinical trials in addition, the following adverse drug reaction was reported in patients who participated in itraconazole capsules clinical trials: hepatobiliary disorders: hyperbilirubinemia. the following is a list of additional adverse drug reactions associated with itraconazole that have been reported in clinical trials of itraconazole oral solution and itraconazole iv excluding the adverse reaction term “injection site inflammation” which is specific to the injection route of administration: cardiac disorders: cardiac failure, left ventricular failure, tachycardia; general disorders and administration site conditions: face edema, chest pain, chills; hepatobiliary disorders: hepatic failure, jaundice; investigations: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, blood urea increased, gamma-glutamyltransferase increased, urine analysis abnormal; metabolism and nutrition disorders: hyperglycemia, hyperkalemia, hypomagnesemia; psychiatric disorders: confusional state; renal and urinary disorders: renal impairment; respiratory, thoracic and mediastinal disorders: dysphonia, cough; skin and subcutaneous tissue disorders: rash erythematous, hyperhidrosis; vascular disorders: hypotension post-marketing experience adverse drug reactions that have been first identified during post-marketing experience with itraconazole (all formulations) are listed in the table below. because these reactions are reported voluntarily from a population of uncertain size, reliably estimating their frequency or establishing a causal relationship to drug exposure is not always possible. table 5: postmarketing reports of adverse drug reactions blood and lymphatic system disorders: leukopenia, neutropenia, thrombocytopenia immune system disorders: anaphylaxis; anaphylactic, anaphylactoid and allergic reactions; serum sickness; angioneurotic edema nervous system disorders: peripheral neuropathy, paresthesia, hypoesthesia, tremor eye disorders: visual disturbances, including vision blurred and diplopia ear and labyrinth disorders: transient or permanent hearing loss cardiac disorders: congestive heart failure respiratory, thoracic and mediastinal disorders: pulmonary edema, dyspnea gastrointestinal disorders: pancreatitis, dysgeusia hepatobiliary disorders: serious hepatotoxicity (including some cases of fatal acute liver failure), hepatitis skin and subcutaneous tissue disorders: toxic epidermal necrolysis, stevens-johnson syndrome, acute generalized exanthematous pustulosis, erythema multiforme, exfoliative dermatitis, leukocytoclastic vasculitis, alopecia, photosensitivity, urticaria musculoskeletal and connective tissue disorders: arthralgia renal and urinary disorders: urinary incontinence, pollakiuria reproductive system and breast disorders: erectile dysfunction general disorders and administration site conditions: peripheral edema investigations: blood creatine phosphokinase increased there is limited information on the use of itraconazole during pregnancy. cases of congenital abnormalities including skeletal, genitourinary tract, cardiovascular and ophthalmic malformations as well as chromosomal and multiple malformations have been reported during post-marketing experience. a causal relationship with itraconazole has not been established (see clinical pharmacology: special populations, contraindications, warnings, and precautions: drug interactions for more information). to report suspected adverse reactions contact avkare, inc. at 1-855-361-3993; email drugsafety@avkare.com ; or fda at 1-800-fda-1088 or www.fda.gov/medwatch .

r doses due to saturable hepatic metabolism. absorption itraconazole is rapidly absorbed after oral administration. peak plasma concentrations of itraconazole are reached within 2 to 5 hours following an oral capsule dose. the observed absolute oral bioavailability of itraconazole is about 55%. the oral bioavailability of itraconazole is maximal when itraconazole capsules are taken immediately after a full meal. absorption of itraconazole capsules is reduced in subjects with reduced gastric acidity, such as subjects taking medications known as gastric acid secretion suppressors (e.g., h 2 -receptor antagonists, proton pump inhibitors) or subjects with achlorhydria caused by certain diseases (see precautions: drug interactions ). absorption of itraconazole under fasted conditions in these subjects is increased when itraconazole capsules are administered with an acidic beverage (such as a non-diet cola). when itraconazole capsules were administered as a single 200-mg dose under fasted conditions with non-diet cola after ranitidine pretreatment, a h 2 -receptor antagonist, itraconazole absorption was comparable to that observed when itraconazole capsules were administered alone (see precautions: drug interactions ). itraconazole exposure is lower with the capsule formulation than with the oral solution when the same dose of drug is given (see warnings ). distribution most of the itraconazole in plasma is bound to protein (99.8%), with albumin being the main binding component (99.6% for the hydroxy-metabolite). it has also a marked affinity for lipids. only 0.2% of the itraconazole in plasma is present as free drug. itraconazole is distributed in a large apparent volume in the body (>700 l), suggesting extensive distribution into tissues. concentrations in lung, kidney, liver, bone, stomach, spleen and muscle were found to be two to three times higher than corresponding concentrations in plasma, and the uptake into keratinous tissues, skin in particular, up to four times higher. concentrations in the cerebrospinal fluid are much lower than in plasma. metabolism itraconazole is extensively metabolized by the liver into a large number of metabolites. in vitro studies have shown that cyp3a4 is the major enzyme involved in the metabolism of itraconazole. the main metabolite is hydroxy-itraconazole, which has in vitro antifungal activity comparable to itraconazole; trough plasma concentrations of this metabolite are about twice those of itraconazole. excretion itraconazole is excreted mainly as inactive metabolites in urine (35%) and in feces (54%) within one week of an oral solution dose. renal excretion of itraconazole and the active metabolite hydroxy-itraconazole account for less than 1% of an intravenous dose. based on an oral radiolabeled dose, fecal excretion of unchanged drug ranges from 3% to 18% of the dose. as re-distribution of itraconazole from keratinous tissues appears to be negligible, elimination of itraconazole from these tissues is related to epidermal regeneration. contrary to plasma, the concentration in skin persists for 2 to 4 weeks after discontinuation of a 4-week treatment and in nail keratin – where itraconazole can be detected as early as 1 week after start of treatment – for at least six months after the end of a 3-month treatment period. special populations: renal impairment: limited data are available on the use of oral itraconazole in patients with renal impairment. a pharmacokinetic study using a single 200-mg oral dose of itraconazole was conducted in three groups of patients with renal impairment (uremia: n=7; hemodialysis: n=7; and continuous ambulatory peritoneal dialysis: n=5). in uremic subjects with a mean creatinine clearance of 13 ml/min. × 1.73 m 2 , the exposure, based on auc, was slightly reduced compared with normal population parameters. this study did not demonstrate any significant effect of hemodialysis or continuous ambulatory peritoneal dialysis on the pharmacokinetics of itraconazole (t max , c max , and auc 0 - 8h ). plasma concentration-versus-time profiles showed wide intersubject variation in all three groups. after a single intravenous dose, the mean terminal half-lives of itraconazole in patients with mild (defined in this study as crcl 50 to 79 ml/min), moderate (defined in this study as crcl 20 to 49 ml/min), and severe renal impairment (defined in this study as crcl <20 ml/min) were similar to that in healthy subjects (range of means 42 to 49 hours vs 48 hours in renally impaired patients and healthy subjects, respectively). overall exposure to itraconazole, based on auc, was decreased in patients with moderate and severe renal impairment by approximately 30% and 40%, respectively, as compared with subjects with normal renal function. data are not available in renally impaired patients during long-term use of itraconazole. dialysis has no effect on the half-life or clearance of itraconazole or hydroxy-itraconazole (see precautions and dosage and administration ). hepatic impairment: itraconazole is predominantly metabolized in the liver. a pharmacokinetic study was conducted in 6 healthy and 12 cirrhotic subjects who were administered a single 100-mg dose of itraconazole as capsule. a statistically significant reduction in mean c max (47%) and a twofold increase in the elimination half-life (37 ± 17 hours vs. 16 ± 5 hours) of itraconazole were noted in cirrhotic subjects compared with healthy subjects. however, overall exposure to itraconazole, based on auc, was similar in cirrhotic patients and in healthy subjects. data are not available in cirrhotic patients during long-term use of itraconazole (see contraindications , precautions : drug interactions and dosage and administration ). decreased cardiac contractility: when itraconazole was administered intravenously to anesthetized dogs, a dose-related negative inotropic effect was documented. in a healthy volunteer study of itraconazole intravenous infusion, transient, asymptomatic decreases in left ventricular ejection fraction were observed using gated spect imaging; these resolved before the next infusion, 12 hours later. if signs or symptoms of congestive heart failure appear during administration of itraconazole capsules, itraconazole should be discontinued (see boxed warning , contraindications , warnings , precautions : drug interactions and adverse reactions : post-marketing experience for more information). microbiology mechanism of action: in vitro studies have demonstrated that itraconazole inhibits the cytochrome p450-dependent synthesis of ergosterol, which is a vital component of fungal cell membranes. activity in vitro and in clinical infections: itraconazole exhibits in vitro activity against blastomyces dermatitidis, histoplasma capsulatum, histoplasma duboisii, aspergillus flavus, aspergillus fumigatus, and trichophyton species (see indications and usage : description of clinical studies ). correlation between minimum inhibitory concentration (mic) results in vitro and clinical outcome has yet to be established for azole antifungal agents. drug resistance: isolates from several fungal species with decreased susceptibility to itraconazole have been isolated in vitro and from patients receiving prolonged therapy. itraconazole is not active against zygomycetes (e.g., rhizopus spp. , rhizomucor spp., mucor spp. and absidia spp.), fusarium spp., scedosporium spp. and scopulariopsis spp. cross-resistance: several in vitro studies have reported that some fungal clinical isolates with reduced susceptibility to one azole antifungal agent may also be less susceptible to other azole derivatives. the finding of cross-resistance is dependent on a number of factors, including the species evaluated, its clinical history, the particular azole compounds compared, and the type of susceptibility test that is performed. studies (both in vitro and in vivo ) suggest that the activity of amphotericin b may be suppressed by prior azole antifungal therapy. as with other azoles, itraconazole inhibits the 14 c-demethylation step in the synthesis of ergosterol, a cell wall component of fungi. ergosterol is the active site for amphotericin b. in one study the antifungal activity of amphotericin b against aspergillus fumigatus infections in mice was inhibited by ketoconazole therapy. the clinical significance of test results obtained in this study is unknown.

o not take itraconazole capsules for fungal nail infections if you have had heart failure, including congestive heart failure. you should not take itraconazole capsules if you are taking certain medicines that could lead to serious or life-threatening medical problems (see “who should not take itraconazole capsules?” below). if you have had heart, lung, liver, kidney or other serious health problems, ask your doctor if it is safe for you to take itraconazole capsules. what happens if i have a fungal nail infection? anyone can have a fungal nail infection, but it is usually found in adults. when a fungus infects the tip or sides of a nail, the infected part of the nail may turn yellow or brown. if not treated, the fungus may spread under the nail towards the cuticle. if the fungus spreads, more of the nail may change color, may become thick or brittle, and the tip of the nail may become raised. in some patients, this can cause pain and discomfort. what are itraconazole capsules? itraconazole capsules are a prescription medicine used to treat fungal infections of the toenails and fingernails. it is also used to treat some types of fungal infections in other areas of your body. we do not know if itraconazole capsules works in children with fungal nail infections or if it is safe for children to take. itraconazole comes in the form of capsules and liquid (oral solution). the capsule and liquid forms work differently, so you should not use one in place of the other. this patient information discusses only the capsule form of itraconazole. you will get these capsules in a medicine bottle. itraconazole goes into your bloodstream and travels to the source of the infection underneath the nail so that it can fight the infection there. improved nails may not be obvious for several months after the treatment period is finished because it usually takes about 6 months to grow a new fingernail and 12 months to grow a new toenail. who should not take itraconazole capsules? itraconazole capsules are not for everyone. your doctor will decide if itraconazole capsules are the right treatment for you. some patients should not take itraconazole capsules because they may have certain health problems or may be taking certain medicines that could lead to serious or life-threatening medical problems. tell your doctor and pharmacist the name of all the prescription and non-prescription medicines you are taking, including dietary supplements and herbal remedies. also tell your doctor about any other medical conditions you have had, especially heart, lung, liver or kidney conditions; or if you have cystic fibrosis, or have had an allergic reaction to itraconazole capsules or any other antifungal medicines. never take itraconazole capsules if you: have had heart failure, including congestive heart failure. are taking any of the medicines listed below. dangerous or even life-threatening side effects could result: cisapride (such as propulsid ® ) colchicine (such as colcrys ™ ) [if you also have pre-existing kidney or liver impairment] disopyramide (such as norpace ® ) dofetilide (such as tikosyn ™ ) dronedarone (such as multaq ® ) eplerenone (such as inspra ® ) ergot alkaloids (such as migranal ® , ergonovine, cafergot ® , methergine ® ) felodipine (such as plendil ® ) fesoterodine (such as toviaz ® ) [if you also have pre-existing kidney or liver impairment] irinotecan (such as camptosar ® ) ivabradine (such as corlanor ® ) lovastatin (such as mevacor ® , advicor ® , altocor ™ ) lurasidone (such as latuda ® ) methadone (such as dolophine ® ) midazolam (such as versed ® ) nisoldipine (such as sular ® ) pimozide (such as orap ® ) quinidine (such as cardioquin ® , quinaglute ® , quinidex ® ) ranolazine (such as ranexa ® ) simvastatin (such as zocor ® ) solifenacin (such as vesicare ® ) [if you also have pre-existing kidney or liver impairment] telithromycin (such as ketek ® ) [if you also have pre-existing kidney or liver impairment] ticagrelor (such as brilinta ® ) triazolam (such as hacion ® ) have ever had an allergic reaction to itraconazole. taking itraconazole capsules with certain other medicines may lead to serious or life-threatening medical problems. tell your doctor and pharmacist the name of all the prescription and non-prescription medicines you are taking, including dietary supplements and herbal remedies. your doctor will decide if itraconazole capsules is the right treatment for you. what should i know about itraconazole capsules and pregnancy or breast feeding? never take itraconazole capsules if you have a fungal nail infection and are pregnant or planning to become pregnant within 2 months after you have finished your treatment. if you are able to become pregnant, you should use effective birth control during itraconazole capsules treatment and for 2 months after finishing treatment. ask your doctor about effective types of birth control. if you are breast-feeding, talk with your doctor about whether you should take itraconazole capsules. how should i take itraconazole capsules? always take itraconazole capsules during or right after a full meal. your doctor will decide the right dose for you. depending on your infection, you will take itraconazole capsules once a day for 12 weeks, or twice a day for 1 week in a dosing schedule. you will receive a bottle of capsules. do not skip any doses. be sure to finish all your itraconazole capsules as prescribed by your doctor. if you have ever had liver problems, your doctor should do a blood test to check your condition. if you haven’t had liver problems, your doctor may recommend blood tests to check the condition of your liver because patients taking itraconazole capsules can develop liver problems. itraconazole capsules can sometimes cause dizziness or blurred/double vision. if you have these symptoms, do not drive or use machines. if you forget to take or miss doses of itraconazole capsules, ask your doctor what you should do with the missed doses. what are the possible side effects of itraconazole capsules? the most common side effects include: headache, and digestive system problems (such as nausea, and abdominal pain). stop itraconazole capsules and call your doctor or get medical assistance right away if you have a severe allergic reaction. symptoms of an allergic reaction may include skin rash, itching, hives, shortness of breath or difficulty breathing, and/or swelling of the face. very rarely, an oversensitivity to sunlight, a tingling sensation in the limbs or a severe skin disorder can occur. if any of these symptoms occur, stop taking itraconazole capsules and contact your doctor. stop itraconazole capsules and call your doctor right away if you develop shortness of breath; have unusual swelling of your feet, ankles or legs; suddenly gain weight; are unusually tired; cough up white or pink phlegm; have unusual fast heartbeats; or begin to wake up at night. in rare cases, patients taking itraconazole capsules could develop serious heart problems, and these could be warning signs of heart failure. stop itraconazole capsules and call your doctor right away if you become unusually tired; lose your appetite; or develop nausea, abdominal pain, or vomiting, a yellow color to your skin or eyes, or dark colored urine or pale stools (bowel movements). in rare cases, patients taking itraconazole capsules could develop serious liver problems and these could be warning signs. stop itraconazole capsules and call your doctor right away if you experience any hearing loss symptoms. in very rare cases, patients taking itraconazole capsules have reported temporary or permanent hearing loss. call your doctor right away if you develop tingling or numbness in your extremities (hands or feet), if your vision gets blurry or you see double, if you hear a ringing in your ears, if you lose the ability to control your urine or urinate much more than usual. additional possible side effects include upset stomach, vomiting, constipation, fever, inflammation of the pancreas, menstrual disorder, erectile dysfunction, dizziness, muscle pain, painful joints, unpleasant taste, or hair loss. these are not all the side effects of itraconazole capsules. your doctor or pharmacist can give you a more complete list. what should i do if i take an overdose of itraconazole capsules? if you think you took too much itraconazole capsules, call your doctor or local poison control center, or go to the nearest hospital emergency room right away. how should i store itraconazole capsules? keep all medicines, including itraconazole capsules, out of the reach of children. store itraconazole capsules at room temperature in a dry place away from light. general advice about itraconazole capsules medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. do not use itraconazole capsules for a condition for which it was not prescribed. do not give itraconazole capsules to other people, even if they have the same symptoms you have. it may harm them. this leaflet summarizes the most important information about itraconazole capsules. if you would like more information, talk with your doctor. you can ask your doctor or pharmacist for information about itraconazole capsules that is written for health professionals or you can call 1-855-361-3993. this patient information has been approved by the u.s. food and drug administration. *all trademarks are property of their respective owner. manufactured for: avkare, inc . pulaski, tn 38478 mfg. rev. 07-2016-00 av 09/17 (p) avpak